- Barrons.com•4 hours ago
BMO's M. Ian Somaiya and team contend that while Gilead Sciences' (GILD) hepatitis-c sales will remain under pressure, its HIV business should make up for it: We sat down with Gilead management during ...
- Business Wire•6 hours agoGilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg for the treatment of direct-acting antiviral -experienced chronic hepatitis C virus -infected patients.
- Forbes•7 hours ago
If a company is not going to get very good pricing for excellent new drugs, then the biopharmaceutical industry will likely stagnate and many new opportunities for drug R&D will not be able to be funded.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||71.33 x 1000|
|Ask||71.34 x 300|
|Day's Range||70.83 - 72.60|
|52 Week Range||70.83 - 104.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.61|
|Dividend & Yield||1.88 (2.60%)|
|1y Target Est||N/A|